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Background: Although G6PD deficiency is the most common genetically determined blood disorder among Iraqis,
its molecular basis has only recently been studied among the Kurds in North Iraq, while studies focusing on Arabs
in other parts of Iraq are still absent.
Methods: A total of 1810 apparently healthy adult male blood donors were randomly recruited from the national
blood transfusion center in Baghdad. They were classified into G6PD deficient and non-deficient individuals based
on the results of methemoglobin reduction test (MHRT), with confirmation of deficiency by subsequent enzyme
assays. DNA from deficient individuals was studied using a polymerase chain reaction-Restriction fragment length
polymorphism (PCR-RFLP) for four deficient molecular variants, namely G6PD Mediterranean (563 C®T), Chatham
(1003 G®A), A- (202 G®A) and Aures (143 T®C). A subset of those with the Mediterranean variant, were further
investigated for the 1311 (C®T) silent mutation.
Results: G6PD deficiency was detected in 109 of the 1810 screened male individuals (6.0%). Among 101 G6PD
deficient males molecularly studied, the Mediterranean mutation was detected in 75 cases (74.3%), G6PD Chatham
in 5 cases (5.0%), G6PD A- in two cases (2.0%), and G6PD Aures in none. The 1311 silent mutation was detected in
48 out of the 51 G6PD deficient males with the Mediterranean variant studied (94.1%).
Conclusions: Three polymorphic variants namely: the Mediterranean, Chatham and A-, constituted more than 80%
of G6PD deficient variants among males in Baghdad. Iraq. This observation is to some extent comparable to other
Asian Arab countries, neighboring Turkey and Iran.
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Background
Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
is the most common human enzyme deficiency affecting
more than 400 million people worldwide [1].
The G6PD gene is located on the Xq28 region of the
X chromosome and is about 20 kb in length comprising
13 exons and 12 introns [2]. Although G6PD is a house
keeping enzyme that is expressed in all tissues, clinical
manifestations of its deficiency are seen almost exclu-
sively in red cells (RBC) including: neonatal jaundice
and acute hemolytic anemia related to drugs, infection,
or the ingestion of fava beans [2,3]
G6PD enzyme (G6PD) is known to protect RBCs from
the harmful effects of reactive oxygen species. Mutations
in G6PD gene that reduce the amount of G6PD enzyme
or alter its structure cause hemolytic anemia as a result
of accumulation of reactive oxygen species [2]. More
than 200 mutations have been reported showing differ-
ent distributions in different populations, with sharing
of specific mutations within each population [4].
G6PD deficiency has been reported in almost all racial
groups with prevalence rates ranging from less than 1%
in Japan and Northern European populations to a high
of 58% in Kurdish Jews [5-7]. High rates of G6PD
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Littoral, Middle East, Africa and south and south East
Asia [1].
Previous studies on G6PD deficiency in Iraq focused
on the prevalence rates in various parts of the country
and among its two major ethnic groups namely: the
Arabs and Kurds [8-12]. Only one study done on the
Kurds of northern Iraq tackled the molecular aspects of
G6PD-deficient variants [12]. The aim of the current
study is to determine the prevalence of G6PD deficiency
and characterize the deficient variants and their enzyme
levels among asymptomatic healthy blood donors in the
Arab population of central Iraq and to compare the
findings with those reported among the Kurds in the
North as well as among neighboring countries.
Methods
A total of 1810 healthy adult male blood donors were
randomly recruited from the National Blood Transfu-
sion Center in Baghdad, Iraq from 28
th April to 26
th
August 2008. They were classified into G6PD deficient
and G6PD non-deficient individuals according to the
result of Methemoglobin Reduction Test (MHRT) [13].
Deficiency was subsequently confirmed by quantitative
enzyme assays according to the manufacturer instruc-
tions (Biolabo-France). G6PD enzyme assays were also
performed on an additional 49 random G6PD non-defi-
cient individuals as controls.
DNA from deficient cases was extracted from whole
blood by phenol-chloroform method. The extracted
DNA was screened sequentially for four G6PD deficient
mutations namely G6PD Mediterranean (563 C®T),
G6PD Chatham (1003 G®A), G6PD A- (202 G®A)
and G6PD Aures (143 T®C). A subset of those with
the Mediterranean variant were then screened for the
silent (1311 C®T) mutation using a polymerase chain
reaction/restriction fragment length polymorphism
(PCR/RFLP) based method [12].
This research was approved by the ethical committee
at the college of Medicine, University of Baghdad, Bagh-
dad-Iraq, and informed consents were obtained from all
participants.
Statistical analysis utilized the Mann Whitney U test,
and a p < 0.05 was considered significant.
Results
Among 1810 individuals enrolled in this study, 109
(6.0%) were found to be deficient by MHRT and then
confirmed by enzyme assays.
Adequately extracted DNA samples from 101 of 109
deficient cases were included in further molecular stu-
dies. The remaining 8 samples were either inadequate
or had failed DNA extraction.
Among 101 G6PD deficient males, the Mediterranean
variant (563 C®T) was detected in 75 (74.3%), G6PD
Chatham (1003 G®A) in 5 (5.0%), and G6PD A- (202
G®A) in 2 (2.0%) individuals. None of the remaining 19
cases showed the G6PD Aures (143 T®C) when tested
for this variant. Table 1 outlines G6PD enzyme levels
among those with the Mediterranean, Chatham and A-
variants as well as the non-deficient controls. The
enzyme levels were least among the Mediterranean, and
they were significantly lower than those with the Cha-
tham variant (p = 0.001).
Among the 101 deficient individuals screened in this
study, only one person with the Mediterranean variant
gave a history suggestive of an acute hemolytic episode
in his childhood, following the ingestion of fava beans
(favism). Family history, however, indicated that in 15
individuals with the Mediterranean variant and 2 with
the Chatham variant, there were episodes suggestive of
acute hemolysis in one or more of their family
members.
Among 51 cases with the Mediterranean variant, 48
(94.1%) showed the presence of the silent 1311 mutation
(1311 C®T).
Discussion
Baghdad lying at the center of Iraq was established as
the Capital at the time of the Abbasid Empire (762-1258
AD). Current day Iraq coincides with ancient Mesopota-
mia that is labeled “the Cradle of Civilization” having
witnessed some of the most ancient civilizations dating
back to 7000 years. This fertile and rich land was
throughout its history an attraction for invaders includ-
ing Persians, Greeks, Romans, Mongols and Turks with
variable impact on the mainly Arab population of Iraq
[14].
G6PD deficiency has long been recognized as a com-
mon inherited hematological disorder among Iraqis [8,9]
with reported rates of 6.0-15.3% [8-12,15]. This study
g a v ear a t eo f6 . 0 %a m o n gm a l e si nB a g h d a d ,af i g u r e
that lies closer to the lower limit of previously reported
range in this city of 6.1-12.3% [8-10]. This might be
explained by the nature of this study where the subjects
were male blood donors; it is expected that blood
Table 1 The G6PD enzyme levels (in IU/g Hb) in the three
deficient variants identified in the current study and the
control non-deficient group
Variant Number Range Mean ± SD Median
Mediterranean 75 0.16-0.89 0.35+0.14 0.35
Chatham 5 0.44-1.17 0.73+0.28 0.71
A- 2 2.10, 1.75
Non-deficient controls 49 8.11-15.1 11.27+2.16 11.20
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who could have experienced the hemolytic anemia of
G6PD deficiency. Studies from Arab and neighboring
countries showed a remarkable variation in the fre-
quency of G6PD deficiency, even within the same coun-
try (Figure 1) [6,16]. Such variation maybe attributed to
variable G6PD gene flow from Southern Europe and
Africa, as well as on the presence of ethnic variations
and the endemicity of malaria. G6PD deficiency is
known to offer selective heterozygote advantage against
certain malaria species in endemic areas [1,2].
The current study revealed that the most common
G6PD deficient molecular variant was G6PD Mediterra-
nean detected in 74.3% of deficient males. The Mediter-
ranean mutation is the most common mutation in
Asian Arab countries and Egypt, with frequencies ran-
ging from a low of 53.6% in Jordan to a high of 91.2%
in Bahrain [17-22], while it is the second most common
variant in some African Arab countries like Algeria and
Tunisia with frequencies of 23% and 11.4% respectively
[23,24]. The Mediterranean mutation is also the most
frequent mutation among Iraqi Kurds (87.8%), in neigh-
boring Turkey (80%), Iran (66.2%-91.2%), Southern Eur-
ope (69-77%) and the Indian subcontinent (60.4-79.6%)
[12,25-32] (Figure 1). The mutation decreases in
frequency as we move east, though it is still present in
polymorphic frequencies in Malaysia and Indonesia
[33,34]. The association of the Mediterranean mutation
with a silent 1311 mutation (1311 C®T) noted in Arab
and other countries in the Middle East as well as south-
ern Europe [21-23,35,36], is consistent with the notion
of the common origin of this mutation in the Mediterra-
nean basin within the past 1600 to 6640 years, and
thereafter spreading to Middle east, and north Africa in
the first millennium BC, where it was selected for by
malaria already highly endemic in these fertile agricul-
tural lands, particularly around 500 BC and thereafter
[37]. In contrast to the latter, studies from Indian sub-
continent (India and Pakistan) have documented that
their Mediterranean mutation is much more likely to be
associated with 1311C, suggesting a separate origin of
the mutation in that part of the world [29,30,36].
The second most frequent variant detected in this
study was G6PD Chatham, which was found in 5.0% of
G6PD deficient individuals. Studies from other Arab
countries showed variable rates of 10.1% in Kuwait,
3.6% in Jordan and 1% in Algeria [17,18,23], while it was
encountered in 8.7% of Iraqi Kurds, 4% in Turkey and
2.2-27% in Iran[12,25-28]. G6PD Chatham is now recog-
nized as one of the common variants worldwide
Figure 1 The prevalence rates of G6PD deficiency and the most common deficient variants among males in Iraq and some of the
surrounding populations [6,8-12,16-32,38,42-56].
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it has also been reported in polymorphic frequencies in
Spain, India, Malaysia and Indonesia [29,33,38,39].
In this study, the African A- variant was present in
only 2% of deficient males, a rate that is lower than the
figures reported in some Asian Arab countries, where it
is the second most common variant with rates of 5.8-
16.7% [17-20]. The A- variant is the most frequent var-
iant in some African Arab countries like Tunisia and
Algeria with rates of 63.6% and 46% respectively [23,24].
The latter is anticipated since the A- mutation is almost
the sole mutation responsible for G6PD deficiency in
tropical Africa (Figure 1) and it is common in areas
where people of African origin are present [2]. Our ear-
lier study on Iraqi Kurds failed to document any case
with the A- variant, while reports from neighboring
Turkey and Iran reported rates of 2% and 0-1.35%
respectively [12,25-28]. Such variability in the distribu-
tion of the African A- mutation could be explained by
the different gene flow of this variant in African and
Asian Arab countries. Future studies in Southern Iraq,
where African gene flow is historically documented, may
show results similar to those found in the Arabian
Peninsula.
G6PD Aures was first described in an Algerian boy in
1993 [40], and later found to account for 7% of deficient
variants in Algeria [23]. Thereafter, reports on this var-
iant appeared from several Arab countries including
Tunisia, Jordan, Kuwait, UAE and Western Saudi Arabia
with frequencies of 4.5, 3.6, 3.0, 16.7 and 17% respec-
tively [17,18,20,24,41]. None of the 19 uncharacterized
cases in the current study showed this variant.
An intriguing observation relevant to the clinical phe-
notype associated with the Mediterranean variant
(known to be a class II severe variant) in the current
study is that only one individual (1.3%) with the latter
variant had a personal history suggestive of favism. This
should be viewed in the context of the design of the
current study, which is based on screening apparently
healthy individuals (blood donors), and maybe due to
several causes including the possibility that some donors
have had mild unnoticeable hemolytic episodes, or that
those with documented favism may have refrained from
blood donation voluntarily. Moreover, it is well known
that hemolysis following bean consumption is not a
rule, with a lot of individual variations even in the same
individual at various times, in addition to the possibility
of yet unidentified genetic factors that may play a role
[1-3]. Our observation is shared by other studies of
comparable design from other populations with predo-
minance of the Mediterranean variant, including Saudi
Arabia and Greece [32,42]. In his study including 757
apparently healthy male volunteers from Eastern Saudi
Arabia, Al-Ali did not find any history of favism in any
of his G6PD deficient subjects, despite the fact that they
constituted 36.5-45.9% of the screened individuals, and
that the Mediterranean variant is known to be their
main deficient variant [19,42]. Another study from
Greece which included screening 7,680 healthy adult
m a l e s ,f o u n dt h a t2 9 9w e r eG 6 P Dd e f i c i e n tw i t ht h e
Mediterranean constituting 77.3% of the variants, yet
none was symptomatic despite quite low enzyme levels
[32]. The results of our study and those reviewed above
favor the notion that many G6PD deficient individuals
in these populations may remain asymptomatic through-
out their lives, unaware of their status [2].
Conclusions
Three polymorphic variants, namely the Mediterranean,
Chatham and A- constituted the bulk of the G6PD defi-
cient variants among the sample population in Baghdad,
a result that is comparable to findings in neighboring
Arab and non-Arab countries. The results of this study
on Iraqi Arabs complement those of our earlier study
on Iraqi Kurds, to give a more comprehensive idea
about the distribution of G6PD variants in Iraq [12]. An
important observation of the current study is that a sig-
nificant number (~19%) of G6PD deficient cases
remained uncharacterized, compared to around ~3% in
our earlier study on Kurds [12], which is quite interest-
ing and may reflect the much open admixture with
other civilizations throughout the centuries [14]. DNA
sequencing is necessary to determine whether these
uncharacterized mutations were carried by gene flow or
they represent novel mutations.
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